EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD

Min-Hsiang Chuang, Hsien-Yi Wang, Wei-Chih Kan, Chih-Chiang Chien iD, Ming-Yan Jiang, Yun-Ting Huang, Vin-Cent Wu iD, Jui-Yi Chen iD

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf064 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Min-Hsiang Chuang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Naphthyridines, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chi-Mei Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and finerenone each improve kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD). This study compares the association between combined therapy versus monotherapy with SGLT2i or finerenone and the kidney, cardiovascular and mortality outcomes in CKD patients.

Methods

This retrospective cohort study included adults ≥18 years with CKD between 9 July 2021, and 30 November 2023 from multiple centers in the USA, utilizing the TriNetX database. Exposures included treatment with finerenone, SGLT2i or a combination of both. The primary outcome was major adverse kidney events (MAKE). Secondary outcomes included all-cause mortality, major adverse cardiac events (MACE) and end-stage renal disease (ESRD).

Results

A total of 853 patients were included in the combined group [mean (±standard deviation) age, 66.7 ± 11.4 years; 34.9% female], 942 in the finerenone group (mean age, 68.2 ± 11.4 years; 45.8% female) and 45 948 in the SGLT2i group (mean age, 70.2 ± 11.8 years; 41.4% female). After matching, the combined group had less MAKE compared with finerenone monotherapy [adjusted hazard ratio (aHR) 0.20; 95% confidence interval (CI) 0.09–0.45] or SGLT2i monotherapy (aHR 0.44; 95% CI 0.22–0.89). The hazards of all-cause mortality and ESRD were also lower in the combined group compared with either finerenone or SGLT2i alone, while hazard of MACE was similar between the combined and monotherapy groups. The combined group had higher risk of hyperkalemia compared with SGLT2i monotherapy (aHR = 1.36; 95% CI 1.08–1.71).

Conclusion

Combined therapy with finerenone and SGLT2i is associated with less MAKE and all-cause mortality in CKD patients compared with monotherapy. However, the risk of hyperkalemia with finerenone warrants caution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesNaphthyridinesRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedDrug Therapy, CombinationFollow-Up StudiesGlomerular Filtration RateKidney Failure, ChronicPrognosisRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

chronic kidney diseasefinerenonemajor adverse cardiac eventsmortalitysodium-glucose cotransporter 2 inhibitors

Substanzen

finerenoneNaphthyridinesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Sport Management, College of Leisure and Recreation Management, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
  • Department of Medical Laboratory Science and Biotechnology, Chung Hwa University of Medical Technology, Tainan, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • NSARF (National Taiwan University Hospital Study Group of ARF) and TAIPAI (Taiwan Primary Aldosteronism Investigators), Taipei, Taiwan.
  • Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.

ORCID-Profile: Chih-Chiang Chien, Vin-Cent Wu, Jui-Yi Chen

Förderung

  • Chi-Mei Medical Center

Zitieren

APA

Chuang, M. H., Wang, H. Y., Kan, W. C., Chien, C. C., Jiang, M. Y., Huang, Y. T., Wu, V. C., & Chen, J. Y. (2025). Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf064

Vancouver

Chuang MH, Wang HY, Kan WC, Chien CC, Jiang MY, Huang YT, et al. Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf064

BibTeX
@article{Chuang2025,
  author = {Chuang, Min-Hsiang and Wang, Hsien-Yi and Kan, Wei-Chih and Chien, Chih-Chiang and Jiang, Ming-Yan and Huang, Yun-Ting and Wu, Vin-Cent and Chen, Jui-Yi},
  title = {Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf064}
}
Kostenlos starten →